Your Advocates Ltd’s Denali Therapeutics DNLI Stock Holding History

Your Advocates Ltd’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-100	Closed	-$1.92K	–	217
2026 Q1	$1.92K	Hold	100	–	–	﹤0.01%	180
2025 Q4	$1.65K	Hold	100	–	–	﹤0.01%	186
2025 Q3	$1.45K	Hold	100	–	–	﹤0.01%	177
2025 Q2	$1.4K	Hold	100	–	–	﹤0.01%	167
2025 Q1	$1.36K	Hold	100	–	–	﹤0.01%	171
2024 Q4	$2.04K	Hold	100	–	–	﹤0.01%	162
2024 Q3	$2.91K	Hold	100	–	–	﹤0.01%	170
2024 Q2	$2.32K	Hold	100	–	–	﹤0.01%	176
2024 Q1	$2.05K	Hold	100	–	–	﹤0.01%	173
2023 Q4	$2.15K	Hold	100	–	–	﹤0.01%	169
2023 Q3	$2.06K	Hold	100	–	–	﹤0.01%	194
2023 Q2	$2.95K	Hold	100	–	–	﹤0.01%	197
2023 Q1	$2.3K	Hold	100	–	–	﹤0.01%	169
2022 Q4	$2.78K	Hold	100	–	–	﹤0.01%	143
2022 Q3	$3K	Hold	100	–	–	﹤0.01%	132
2022 Q2	$3K	Hold	100	–	–	﹤0.01%	137
2022 Q1	$3K	Hold	100	–	–	﹤0.01%	154
2021 Q4	$4K	Buy	+100	New	+$4.74K	﹤0.01%	129

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Your Advocates Ltd's DNLI Position: Q2 2026 in Review

Your Advocates Ltd sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 100 shares — an estimated $1.92K sold.

Your Advocates Ltd first reported a position in DNLI in Q4 2021 and held it in 18 quarters. The position peaked at $4K in Q4 2021. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Your Advocates Ltd reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
Your Advocates Ltd sold 100 Denali Therapeutics shares in Q2 2026, an estimated $1.92K.
Your Advocates Ltd first reported a position in Denali Therapeutics in Q4 2021 and held it in 18 quarters.
Your Advocates Ltd's Denali Therapeutics position peaked at $4K in Q4 2021.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Your Advocates Ltd's 13F filing for Q2 2026, filed 5 Aug 2026.